medeor's cellular products (Medeor Therapeutics)
Structured Review
Medeor's Cellular Products, supplied by Medeor Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/medeor+matrix/nct05010174-1-24-24
Average 90 stars, based on 1 article reviews
Images
Related Articles
CRISPR:Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: Long-term safety of subjects treated with Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: At the completion of primary Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Have previously completed a Medeor study and received a Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects Article Snippet: Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: The study population will consist of kidney transplant recipients who received Transplantation Assay:Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: Long-term safety of subjects treated with Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: At the completion of primary Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Have previously completed a Medeor study and received a Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects Article Snippet: Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: The study population will consist of kidney transplant recipients who received In Utero:Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: Long-term safety of subjects treated with Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: At the completion of primary Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Have previously completed a Medeor study and received a Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects Article Snippet: Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: The study population will consist of kidney transplant recipients who received Plasmid Preparation:Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: Long-term safety of subjects treated with Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: At the completion of primary Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Have previously completed a Medeor study and received a Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects Article Snippet: Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: The study population will consist of kidney transplant recipients who received Virus:Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: Long-term safety of subjects treated with Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: At the completion of primary Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Have previously completed a Medeor study and received a Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects Article Snippet: Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: The study population will consist of kidney transplant recipients who received Variant Assay:Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: Long-term safety of subjects treated with Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: At the completion of primary Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Have previously completed a Medeor study and received a Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects Article Snippet: Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: The study population will consist of kidney transplant recipients who received Transduction:Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: Long-term safety of subjects treated with Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: At the completion of primary Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Have previously completed a Medeor study and received a Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects Article Snippet: Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: The study population will consist of kidney transplant recipients who received Genetically Modified:Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products Article Snippet: Long-term safety of subjects treated with Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: At the completion of primary Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Have previously completed a Medeor study and received a Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects Article Snippet: Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE Article Snippet: The study population will consist of kidney transplant recipients who received |


